March 2, 2021; 1-2 p.m.
Medication Options for Treatment of Stimulant Use Disorders:
Optimistic Update and New Research
Overdose deaths associated with illicit stimulants (cocaine and methamphetamine) have surged in the past eight years, according to a recent study by the National Institutes for Health (NIH). While there are currently no FDA-approved medications for the treatment of individuals who are dependent on stimulants, new treatments utilizing readily available medications are showing encouraging empirical support.
Join us for “Medication Options for Treatment of Stimulant Use Disorders: Optimistic Update and New Research,” when we’ll examine the latest groundbreaking research in the context of current increases in stimulant use. Marc Fishman, MD, medical director of Maryland Treatment Centers, a member of the psychiatry faculty of the Johns Hopkins University School of Medicine, and a member of the National Council’s Medical Director Institute will share his expertise as an addiction medicine specialist to bring the latest information to help you:
- Understand the current epidemiology of stimulant use in the U.S.
- Address the most common clinical challenges in treating people with stimulant use disorders.
- Explore new research that provides evidence for potential treatment of stimulant use disorder treatment.
With two COVID-19 vaccines now in distribution, and more on the way, many employers have asked about the legalities involved in asking employees to become vaccinated. This presentation will provide guidance for employers to help navigate questions related to the FDA’s emergency use authorization, mandatory vaccination policies, and employee requests for disability-related and religious accommodations.